Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31697814)

  • 1. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
    Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
    Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
    J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
    Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
    Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
    Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
    Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
    Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
    Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
    Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
    Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
    Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Ngu HS; Savage KJ
    Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
    Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
    Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
    Sharman JP; Wheler JJ; Einhorn L; Dowlati A; Shapiro GI; Hilton J; Burke JM; Siddiqi T; Whiting N; Jalal SI
    Invest New Drugs; 2019 Aug; 37(4):738-747. PubMed ID: 30993587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
    Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
    Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.